Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 September 29, 2023 14:00 CET Non Regulatory Read more
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU September 28, 2023 12:01 CET Non Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib September 27, 2023 19:06 CET Non Regulatory Read more
Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo September 19, 2023 16:00 CET Non Regulatory Read more
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet August 15, 2023 08:00 CET Non Regulatory Read more
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib July 13, 2023 08:00 CET Non Regulatory Read more
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO[®] June 21, 2023 09:00 CET Non Regulatory Read more
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 May 5, 2023 14:30 CET Non Regulatory Read more
Calliditas to participate in upcoming investor conferences March 31, 2023 17:00 CET Non Regulatory Read more
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy February 2, 2023 09:15 CET Non Regulatory Read more
